This grant opportunity from the Food and Drug Administration supports clinical trials that address unmet needs in rare neurodegenerative diseases. It is an R01 mechanism requiring clinical trials, with a deadline in May 2026. Specific eligibility and funding details are not provided in the listing.
Eligibility details are not specified in the grant listing. Contact the funding organization for requirements.
